Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Study Number

503719

Phase

Age Group

Adult

Principal Investigator

Purpose

The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.

Check your eligibility for this trial

Check now

Full Title

A Phase II Study of Pembrolizumab and Entinostat in Patients with Relapsed and Refractory Lymphomas (17-073)

ClinicalTrials.Gov ID

NCT03179930

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.